199 related articles for article (PubMed ID: 31605696)
1. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C
BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203
[TBL] [Abstract][Full Text] [Related]
3. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
5. Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.
Miao Y; Konno Y; Wang B; Zhu L; Zhai T; Ihira K; Kobayashi N; Watari H; Jin X; Yue J; Dong P; Fang M
J Transl Med; 2023 Feb; 21(1):151. PubMed ID: 36829176
[TBL] [Abstract][Full Text] [Related]
6. Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway.
Zhang L; Jiang B; Zhu N; Tao M; Jun Y; Chen X; Wang Q; Luo C
Med Oncol; 2019 Nov; 37(1):5. PubMed ID: 31720873
[TBL] [Abstract][Full Text] [Related]
7. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
8. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
[TBL] [Abstract][Full Text] [Related]
10. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
Miao R; Wu Y; Zhang H; Zhou H; Sun X; Csizmadia E; He L; Zhao Y; Jiang C; Miksad RA; Ghaziani T; Robson SC; Zhao H
Sci Rep; 2016 Sep; 6():33121. PubMed ID: 27618777
[TBL] [Abstract][Full Text] [Related]
11. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion.
Wen YA; Zhou BW; Lv DJ; Shu FP; Song XL; Huang B; Wang C; Zhao SC
Asian J Androl; 2018; 20(2):178-183. PubMed ID: 29271400
[TBL] [Abstract][Full Text] [Related]
12. Silencing of MEOX1 Gene Inhibits Proliferation and Promotes Apoptosis of LNCaP Cells in Prostate Cancer.
Zhu ZY; Wang XL; Li DP
Cancer Biother Radiopharm; 2019 Mar; 34(2):91-102. PubMed ID: 30543460
[TBL] [Abstract][Full Text] [Related]
13. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
Chen X; Yu C; Gao J; Zhu H; Cui B; Zhang T; Zhou Y; Liu Q; He H; Xiao R; Huang R; Xie H; Gao D; Zhou H
Theranostics; 2018; 8(9):2348-2360. PubMed ID: 29721084
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
[TBL] [Abstract][Full Text] [Related]
16. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.
Wang T; Abou-Ouf H; Hegazy SA; Alshalalfa M; Stoletov K; Lewis J; Donnelly B; Bismar TA
J Mol Med (Berl); 2016 Dec; 94(12):1411-1422. PubMed ID: 27534968
[TBL] [Abstract][Full Text] [Related]
17. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
18. TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
Lin M; Bu C; He Q; Gu J; Wang H; Feng N; Jiang SW
Oncol Rep; 2020 Aug; 44(2):747-756. PubMed ID: 32468018
[TBL] [Abstract][Full Text] [Related]
19. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
